2022
EBAG9-silencing exerts an immune checkpoint function without aggravating adverse effects.
Wirges, A., Bunse, M., Joedicke, J.J., Blanc, E., Gudipati, V., Moles, M.W., Shiku, H., Beule, D., Huppa, J.B., Höpken, U.E. and Rehm, A.
Molecular Therapy 30
(11): 3358-3378.
2 November 2022
Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single cell transcriptomics.
Wyler, E., Adler, J.M., Eschke, K., Teixeira Alves, G., Peidli, S., Pott, F., Kazmierski, J., Michalick, L., Kershaw, O., Bushe, J., Andreotti, S., Pennitz, P., Abdelgawad, A., Postmus, D., Goffinet, C., Kreye, J., Reincke, S.M., Prüss, H., Blüthgen, N., Gruber, A.D., Kuebler, W.M., Witzenrath, M., Landthaler, M., Nouailles, G. and Trimpert, J.
Molecular Therapy 30
(5): 1952-1965.
4 May 2022
2020
CRISPR/Cas9-mediated ELANE mutation correction in hematopoietic stem and progenitor cells to treat severe congenital neutropenia.
Tran, N.T., Graf, R., Wulf-Goldenberg, A., Stecklum, M., Strauß, G., Kühn, R., Kocks, C., Rajewsky, K. and Chu, V.T.
Molecular Therapy 28
(12): 2621-2634.
2 December 2020
Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system.
Rotiroti, M.C., Buracchi, C., Arcangeli, S., Galimberti, S., Valsecchi, M.G., Perriello, V.M., Rasko, T., Alberti, G., Magnani, C.F., Cappuzzello, C., Lundberg, F., Pande, A., Dastoli, G., Introna, M., Serafini, M., Biagi, E., Izsvák, Z., Biondi, A. and Tettamanti, S.
Molecular Therapy 28
(9): 1974-1986.
2 September 2020
2018
CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin's lymphoma and multiple myeloma.
Bluhm, J., Kieback, E., Marino, S.F., Oden, F., Westermann, J., Chmielewski, M., Abken, H., Uckert, W., Höpken, U.E. and Rehm, A.
Molecular Therapy 26
(8): 1906-1920.
1 August 2018
Efficient non-viral gene delivery into human hematopoietic stem cells by minicircle Sleeping Beauty transposon vectors.
Holstein, M., Mesa-Nuñez, C., Miskey, C., Almarza, E., Poletti, V., Schmeer, M., Grueso, E., Ordóñez Flores, J.C., Kobelt, D., Walther, W., Aneja, M.K., Geiger, J,, Bonig, H.B., Izsvák, Z., Schleef, M., Rudolph, C., Mavilio, F., Bueren, J.A., Guenechea, G. and Ivics, Z.
Molecular Therapy 26
(4): 1137-1153.
4 April 2018
2016
Structural determinants of sleeping beauty transposase activity.
Abrusán, G., Yant, S.R., Szilágyi, A., Marsh, J.A., Mátés, L., Izsvák, Z., Barabás, O. and Ivics, Z.
Molecular Therapy 24
(8): 1369-1377.
August 2016
Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T cells.
Gogol-Döring, A., Ammar, I., Gupta, S., Bunse, M., Miskey, C., Chen, W., Uckert, W., Schulz, T.F., Izsvák, Z. and Ivics, Z.
Molecular Therapy 24
(3): 592-606.
March 2016
Sleeping Beauty transposon vectors in liver directed gene delivery of LDLR and VLDLR for gene therapy of familial hypercholesterolemia.
Turunen, T.A.K., Kurkipuro, J., Heikura, T., Vuorio, T., Hytönen, E., Izsvák, Z. and Ylä-Herttuala, S.
Molecular Therapy 24
(3): 620-635.
March 2016
2014
RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer.
Bunse, M., Bendle, G.M., Linnemann, C., Bies, L., Schulz, S., Schumacher, T.N. and Uckert, W.
Molecular Therapy 22
(11): 1983-1991.
November 2014
2012
Retargeting Sleeping Beauty transposon insertions by engineered zinc finger DNA-binding domains.
Voigt, K., Gogol-Doering, A., Miskey, C., Chen, W., Cathomen, T., Izsvak, Z. and Ivics, Z.
Molecular Therapy 20
(10): 1852-1862.
October 2012
2011
Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells.
Moldt, B., Miskey, C., Staunstrup, N.H., Gogol-Doering, A., Bak, R.O., Sharma, N., Mates, L., Izsvak, Z., Chen, W., Ivics, Z. and Mikkelsen, J.G.
Molecular Therapy 19
(8): 1499-1510.
August 2011
2010
Comparative analysis of transposable element vector systems in human cells.
Grabundzija, I., Irgang, M., Mates, L., Belay, E., Matrai, J., Gogol-Doering, A., Kawakami, K., Chen, W., Ruiz, P., Chuah, M.K., Vandendriessche, T., Izsvak, Z. and Ivics, Z.
Molecular Therapy 18
(6): 1200-1209.
June 2010
2009
Hybrid lentivirus-transposon vectors with a random integration profile in human cells.
Staunstrup, N.H., Moldt, B., Mates, L., Villesen, P., Jakobsen, M., Ivics, Z., Izsvak, Z. and Mikkelsen, J.G.
Molecular Therapy 17
(7): 1205-1214.
July 2009
2008
Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators.
Walisko, O., Schorn, A., Rolfs, F., Devaraj, A., Miskey, C., Izsvak, Z. and Ivics, Z.
Molecular Therapy 16
(2): 359-369.
February 2008
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.
Stein, U., Walther, W., Stege, A., Kaszubiak, A., Fichtner, I. and Lage, H.
Molecular Therapy 16
(1): 178-186.
January 2008
2007
Targeted Sleeping Beauty transposition in human cells.
Ivics, Z., Katzer, A., Stuewe, E.E., Fiedler, D., Knespel, S. and Izsvak, Z.
Molecular Therapy 15
(6): 1137-1144.
June 2007
2005
Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma.
Walther, W., Stein, U., Fichtner, I., Kobelt, D., Aumann, J., Arlt, F. and Schlag, P.M.
Molecular Therapy 12
(6): 1176-1184.
29 September 2005
2004
Sleeping Beauty transposition: biology and applications for molecular therapy.
Izsvak, Z. and Ivics, Z.
Molecular Therapy 9
(2): 147-156.
1 February 2004
Development of hyperactive Sleeping Beauty transposon vectors by mutational analysis.
Zayed, H., Izsvak, Z., Walisko, O. and Ivics, Z.
Molecular Therapy 9
(2): 292-304.
1 February 2004
2000
Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo.
Armeanu, S., Pelisek, J., Krausz, E., Fuchs, A., Groth, D., Curth, R., Keil, O., Quilici, J., Rolland, P.H., Reszka, R. and Nikol, S.
Molecular Therapy 1
(4): 366-375.
1 April 2000
Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk.
Morris, J.C. and Wildner, O.
Molecular Therapy 1
: 56-62.
1 January 2000
This list was generated on Mon Nov 11 17:06:21 2024 UTC.